Adaptin Bio, Inc. SEC filings APTN
Adaptin Bio, Inc. has 75 filings in SEC EDGAR's recent list, going back to Aug 10, 2023. Its latest annual report, Form 10-K, was filed on Apr 1, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 25, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 424B3 | Prospectus | Sep 10, 2026 | — |
| S-1 | Registration statement | Aug 28, 2026 | — |
| 424B3 | Prospectus | Aug 25, 2026 | — |
| 424B3 | Prospectus | Aug 20, 2026 | — |
| POS AM | Post-effective amendment no. 1 to form s-1 | Jul 21, 2026 | — |
| 424B3 | Prospectus | Jun 12, 2026 | — |
| 424B3 | Prospectus | May 18, 2026 | — |
| 424B3 | Prospectus | Nov 17, 2025 | — |
| 424B3 | Prospectus | Oct 7, 2025 | — |
| S-8 | Employee stock plan registration | Aug 15, 2025 | — |
| 424B3 | Prospectus | Aug 15, 2025 | — |
| 424B3 | Prospectus | Aug 5, 2025 | — |
| S-1/A | Amended registration statement | Jul 28, 2025 | — |
| S-1/A | Amended registration statement | Jun 27, 2025 | — |
| S-1 | Registration statement | May 16, 2025 | — |
Showing 15 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- APTN (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Charlotte, NC
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1938571
- Former names
- Unite Acquisition 1 Corp. (until Feb 13, 2025)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.